-+ 0.00%
-+ 0.00%
-+ 0.00%

Trop2 ADC gastroesophageal adenocarcinoma phase III study in collaboration with MSD reached the main end point

Zhitongcaijing·11/20/2026 12:57:03
Listen to the news

The Zhitong Finance App learned that the research TROP2 targeted antibody drug conjugate (ADC) sacituzumab tirumotecan (Sac-TMT), developed in collaboration with MSD (MRK.US), reached the main end point of overall survival (OS) in a critical phase III Trofuse-015 study. SAC-TMT is the world's first TROP2 ADC in advanced gastroesophageal adenocarcinoma patients to improve OS compared to doctors' choice (TPC) in a global phase III study; these patients have previously received two or more lines of systemic treatment.

The Trofuse-015 study evaluated SAC-TMT for the treatment of locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. The TPC regimen for comparison included trifluoruridine tepypyrimidine, irinotecan, paclitaxel, or docetaxel. This is the first time that TROP2 ADC has proven OS benefits in a global phase III trial in this patient population, and there is significant unmet demand in this area. Relevant data will be presented at upcoming medical conferences and shared with regulators.

The final analysis showed that for the above patients who had received two or more lines of systemic treatment in the past, sAC-TMT achieved a statistically significant and clinically significant improvement in OS compared to TPC. Results were generally consistent across subgroups regardless of TROP2 expression status. Sac-TMT did not reach the progression-free survival (PFS) secondary endpoint assessed by the Blind Independent Center (BICR). Furthermore, the objective response rate (ORR), which is a secondary endpoint, numerically showed a favorable improvement in sAC-TMT, but was not formally tested according to the pre-set analysis plan. The safety characteristics were consistent with previously reported sAC-TMT studies, and no new safety signals were observed.

Dr. Marjorie Green, senior vice president and head of global clinical development oncology at MSD Research Laboratories, said, “SaC-TMT is the world's first TROP2 ADC to improve OS compared to TPC in a global phase III study of advanced gastroesophageal adenocarcinoma, showing its potential in this particularly challenging disease scenario. These patients have a huge unmet need for treatments that improve survival. We look forward to representing potentially benefiting patients, discussing this data with regulators and sharing it with the scientific community.”

Trofuse-015 is also the second positive phase III study from MSD's SAC-TMT Trofuse clinical development program. The project currently includes 18 ongoing global phase III trials, covering more diseases and treatment scenarios than any ADC targeting TROP2 to date. The project is evaluating SAC-TMT for various tumors such as endometrial cancer, bladder cancer, breast cancer, cervical cancer, gastric cancer, non-small cell lung cancer, and ovarian cancer, covering early to advanced diseases, both as a single agent and in combination with immunotherapy. Among the 18 Phase III studies in this project, 14 are exploring first-in-class (first-in-class) opportunities to address unmet medical needs, and Trofuse-015 is one of them.

According to public information, as an innovative drug platform within the Colon system, Collombotai has accumulated more than ten years of ADC research and development experience, making it the first Chinese company to establish ADC cooperation with the top ten multinational pharmaceutical companies. Sac-TMT (lucan satuzumab, trade name: Cathailai®) is the company's core product and the world's first TROP2 ADC approved for lung cancer. It has now been approved for 4 indications in China, covering triple-negative breast cancer, EGFR mutant non-small cell lung cancer, and HR+/HER2-breast cancer. The first 2 of these are covered by medical insurance; the drug has also been certified as a breakthrough therapy by the State Drug Administration.

SAC-TMT's overseas rights stem from an authorization in May 2022. At that time, Collumbotai exclusively granted MSD the right to develop, use, manufacture and commercialize the drug (SKB264, MSD number MK-2870) outside of Greater China, and received non-refundable payments of 17 million US dollars and 30 million US dollars respectively when the agreement came into effect and after the amendments were signed. The cumulative milestone payments did not exceed US$1,363 million, and tiered commissions were charged based on net sales. Since then, the two sides have successively approved SKB315 and 7 pre-clinical ADC assets, and the total initial grant milestone since May 2022 can exceed US$11.8 billion. Currently, all overseas clinical studies of SAC-TMT are sponsored and led by MSD.